NEUROLOGICAL REVIEW

SECTION EDITOR: DAVID E. PLEASURE, MD

Paroxysmal Autonomic Instability With Dystonia After Brain Injury

James A. Blackman, MD, MPH; Peter D. Patrick, PhD; Marcia L. Buck, PharmD; Robert S. Rust, Jr, MD

complication of severe brain injury is a syndrome of intermittent agitation, diaphoresis, hyperthermia, hypertension, tachycardia, tachypnea, and extensor posturing. To capture the main features of this syndrome, derived through literature review and our own case series, we propose the term paroxysmal autonomic instability with dystonia. We reviewed reports of autonomic dysregulation after brain injury and extracted essential features. From the clinical features, consistent themes emerge regarding signs and symptoms, differential diagnosis, and pharmacological therapies. We used these findings to make recommendations regarding diagnosis and treatment. Paroxysmal autonomic instability with dystonia appears to be a distinctive syndrome after brain injury that can mimic other life-threatening conditions. Early recognition may lead to fewer diagnostic tests and a rational approach to management. Prospective trials of specific drugs are needed to determine optimal efficacy. Arch Neurol. 2004;61:321-328
A complication of severe brain injury, regardless of etiology, is a syndrome of marked agitation, diaphoresis, hyperthermia, hypertension, tachycardia, and tachypnea accompanied by hypertonia and extensor posturing. Usually episodic, it first appears in the intensive care setting but may persist into the rehabilitation phase for weeks to months after injury in individuals who remain in a low-response state. The syndrome engenders alarm because it may be difficult to distinguish from life-threatening conditions such as sepsis, impending herniation, or epileptic seizure. These manifestations could lead to secondary hypertensive or hyperthermic encephalopathy and even death. Various labels have been applied to this phenomenon, such as paroxysmal sympathetic storms, diencephalic seizures, or midbrain dysregulatory syndrome. However, the syndrome remains poorly understood and underrecognized, despite its distinctive and characteristic features. The
From the Kluge Childrens Rehabilitation Center, Department of Pediatrics (Drs Blackman, Patrick, and Buck), and the Division of Pediatric Neurology, Department of Neurology (Dr Rust), University of Virginia, Charlottesville.

lack of a standardized nomenclature is a major problem with research into this condition.1 Based on a review of limited existing literature, generally consisting of reports of a single or only a few cases, and of our own case series, we propose the following name for this syndrome: paroxysmal autonomic instability with dystonia (PAID). We will define its characteristics as precisely as possible, provide guidelines for distinguishing it from other conditions with similar characteristics, and suggest a rational treatment approach. The pathophysiology of PAID can be best explained by dysfunction of autonomic centers in the diencephalon (thalamus or hypothalamus) or their connections to cortical, subcortical, and brainstem loci that mediate autonomic function. Bullard2 suggested a release phenomenon in which loss of cortical and subcortical control of vegetative functions occurs, including regulation of blood pressure and temperature. Boeve et al3 expanded this concept by speculating that the mechanism likely involves activation (or disinhibition) of central sympathoexcitatory regions such as the para-

(REPRINTED) ARCH NEUROL / VOL 61, MAR 2004 321

WWW.ARCHNEUROL.COM

2004 American Medical Association. All rights reserved. Downloaded From: http://archneur.jamanetwork.com/ on 06/10/2013

ventricular hypothalamic nucleus, lateral periaqueductal gray substance, lateral parabrachial nucleus, or rostral ventricular medulla. Cortically provoked release of adrenomedullary catecholamines during PAID episodes may contribute to the rise in blood pressure as well as tachycardia and tachypnea.4,5 Thermoregulatory dysfunction may also be produced by hypothalamic dysfunction, as has been demonstrated experimentally6 and clinically. The temperature elevations associated with PAID may also be explained, at least in part, by the hypermetabolic state that accompanies sustained muscular contractions. Rigidity and decerebrate posturing are seen experimentally and clinically with lesions in the midbrain, blocking normal inhibitory signals to pontine and vestibular nuclei.7 This allows these nuclei to become tonically active, transmitting facilitatory signals to the spinal cord control circuits. Spinal reflexes become hyperexcitable, evoked by sensory input signals that are usually below the threshold for excitation of a motor response. LITERATURE REVIEW Episodic agitation, diaphoresis, hyperthermia, tachycardia, tachypnea, and rigid decerebrate posturing after severe brain injury were first noted in a report by Strich in 1956.8 He called these events brainstem attacks. Subsequently, this constellation of clinical signs has received a variety of labels, including autonomic dysfunction syndrome, fever of central origin, neurostorming, acute midbrain syndrome, hypothalamic-midbrain dysregulation syndrome, hyperpyrexia associated with sustained muscle contractions, dysautonomia, sympathetic storms, paroxysmal sympathetic storms, acute hypothalamic instability, and diencephalic seizures. Table 1 provides a summary of the clinical features of relevant case reports. We have included a series of our own patients. Permission was obtained from the Human Investigation Committee, University of Virginia, Charlottesville, to review patient records for this report. Because some of these patients received intensive care at other hospitals and their daily nursing and physician notes were not available, it was not possible to determine the time of initial onset of PAID signs or their total duration. Although some heterogeneity in manifestations has been noted, there is a sufficient degree of uniformity to justify viewing these cases as a syndrome. The cases have in common autonomic dysregulation and rigidity due to dystonia (involuntary sustained muscle contraction and extensor posturing). The PAID syndrome has been reported in children and adults. Traumatic and hypoxic brain injury account for most cases, but some were due to tumors, intracranial hemorrhage, or hydrocephalus. It is most likely to be encountered after processes that produce diffuse axonal or brainstem injury. The onset of PAID signs often occurs in the first week after severe brain injury, when differential diagnosis is most difficult, and continues for weeks to months, in some cases for longer than 1 year. We have found that the episodes tend to persist the longest in patients with brain injury due to anoxia. Early diagnosis is challenging be(REPRINTED) ARCH NEUROL / VOL 61, MAR 2004 322

cause the various constituent parts of the syndrome may be caused by a wide variety of processes that may occur in these very ill patients, including seizures, infection, the effects of drugs, withdrawal from drug therapy, pain, or agitation. PAID signs occur at a time when the patients mental status is abnormal, and tests such as electroencephalography may be difficult to obtain or coordinate with the intermittent phenomena. These signs invariably include temperature elevation (as high as 41C), increases in heart and breathing rates, hypertension, diaphoresis, agitation, and extensor posturing. Creatine kinase levels are rarely reported; in one case these values were within the reference range, and in another, elevated. The most commonly used drugs for treatment of PAID are morphine sulfate, bromocriptine mesylate, propranolol hydrochloride, clonidine hydrochloride, lorazepam, and dantrolene sodium. Each one of these drugs is rational and addresses a component of the PAID syndrome (Table 2). Opioid receptors are found in brain cardiovascular nuclei, the heart, and blood vessels.20 Opiates such as morphine, when peripherally injected into healthy animals, produce hypotension.21 Morphine induces analgesia, respiratory depression, and bradycardia. Its analgesic properties may interfere with pain as an inciting factor, and its sedative effects may counter the tachycardia and tachypnea. Constipation is a problematic adverse effect of morphine and narcotic dependency. Withdrawal from opiate therapy may provoke signs that falsely suggest PAID. The use of dopamine antagonists or the withdrawal of dopamine agonist therapy may also result in neuroleptic malignant syndrome (NMS), the clinical features of which suggest PAID. Thus, it is not surprising that the use of bromocriptine, a dopamine agonist, has been found to be helpful in PAID. Because excitation of the sympathetic nervous system appears to be a major feature of PAID, the uses of -adrenergic blockade, such as propranolol (nonselective -adrenergic blockade) or labetalol hydrochloride (nonselective - plus 1-adrenergic blockade), are logical choices and have proven clinically useful in the amelioration of some of the most important clinical signs (eg, hypertension), but not cholinergic signs (eg, diaphoresis) of PAID. In the experience of Do et al,9 1-adrenergic selective antagonists (eg, metoprolol or atenolol) are not effective, as in mitigating autonomic dysregulation. Clonidine, an 2-adrenergic agonist, reduces blood pressure, has a behavior-stabilizing effect, and causes sedation. These features treat the sympathetic signs and may interrupt feedback into the system that otherwise would perpetuate the cycle of autonomic dysregulation. The benzodiazepines, such as lorazepam, have anxiolytic and sedating effects and muscle relaxant properties that may account for benefits observed in treatment of PAID. In addition to its direct muscle relaxant properties, dantrolene may diminish fever due to prolonged muscle contraction and may also reduce the somatosympathetic spinal reflexes that contribute to sympathetic excitation.
WWW.ARCHNEUROL.COM

2004 American Medical Association. All rights reserved. Downloaded From: http://archneur.jamanetwork.com/ on 06/10/2013

Table 1. Reports of Patients With Paroxysmal Autonomic Instability With Dystonia

No. of Cycles Onset, d per Day NA NA Duration of Each Episode NA

Source University of Virginia

No. of Subjects 7

Age, y 9-29

Origin MVC, near drowning, hanging, assault

Total Duration NA

Signs

Treatment or Drugs

Term Used to Describe NA

Thorley et al,12 2001

20

MVC

NA

Cuny et al,11 2001 Do et al,9 2000

17-37

MVC

24-60

2-16

21

MVC

450

Baguley,1 1999 Goh et al,10 1999

14

NA

Hypoxia, TBI

NA

NA

Midbrain glioma

NA

Boeve et al,3 1998

17

MVC

1-3

Scott et al,13 1997

11

Hydrocephalus, tumor

NA

2-4

Sneed,14 1995

Near drowning

14

NA

T, 38C-41.8C; HR, Atenolol, 161-216 beats/min; lorazepam, BP, 123-171/78-101 diazepam, mm Hg; rigid or methadone decerebrate hydrochloride, posturing; propranolol diaphoresis; agitation hydrochloride, clonidine hydrochloride Minutes to 2 wk T, 40.0C; HR, 156 Midazolam, hours beats/min; extremity lorazepam, posturing; morphine diaphoresis; sulfate, agitation; CPK, 61 oxycodone, U/L bromocriptine mesylate, dantrolene sodium NA 1-8 wk Hyperthermia; Intrathecal hypertonia; baclofen tachycardia 1-2 h NA T, 39.1 C; HR, 140-160 Labetalol beats/min; BP, hydrochloride 170-180/100 mm Hg; diaphoresis; flexor posturing NA NA Classic features NA described by Boeve et al3 (1998) NA NA T, 38.4C-39.5C; HR, Phenytoin sodium, 150-180 beats/min; diazepam, SBP, 180 mm Hg; lorazepam, DBP, 120 mm Hg; clonidine sweating, muscle spasms; decorticate posturing; nystagmus; teeth grinding 2-4, 12 mo T, 39C-42C; HR, Morphine, 8-10 h 140-190 beats/min; bromocriptine, RR, 26-40 dantrolene breaths/min; SBP, sodium 150-170 mm Hg; increased decerebrate/ opisthotonic posturing 2-6 h NA T, 39C-42C; HR, Chlorpromazine 140-160 beats/min; hydrochloride, RR, 30-60 bromocriptine, breaths/min; SBP, propranolol, 160 mm Hg; DBP, levodopa/ 110-120 mm Hg; carbidopa diaphoresis; increased muscle tone; tremors Days to a 85 wk T, 39.5C; diaphoresis; Clonazepam week opisthotonic posturing; increased CPK level NA NA Tachycardia; T, Propranolol 38.9C-40.6C; sweating; decorticate posturing

Acute hypothalamic instability

Dysautonomia

Paroxysmal sympathetic storm

Paroxysmal sympathetic storms Diencephalic seizures

Paroxysmal sympathetic storms (diencephalic seizures)

Hypothalamic storming

Meythaler and Stinson,15 1994

15, 20, 21

TBI

NA

NA

Hyperpyrexia associated with sustained muscle contractions Fever of central origin

(continued)

(REPRINTED) ARCH NEUROL / VOL 61, MAR 2004 323

WWW.ARCHNEUROL.COM

2004 American Medical Association. All rights reserved. Downloaded From: http://archneur.jamanetwork.com/ on 06/10/2013

Table 1. Reports of Patients With Paroxysmal Autonomic Instability With Dystonia (cont)
No. of Duration Cycles of Each Total Onset, d per Day Episode Duration 6 1-6 NA NA

Source Pranzatelli et al,16 1991

No. of Subjects 3

Age, y 7-19

Origin Hypothalamic astrocytoma, MVC, CHI

Signs

Treatment or Drugs

Term Used to Describe Hypothalamicmidbrain dysregulation syndrome

Rossitch and Bullard,17 1988

NA

6 CHI, 2 hydrocephalus, 1 ICH

NA

Minutes to hours

NA

Talman et al,18 1988

26, 57

Acute hydrocephalus

NA

NA

NA

NA

Bullard,2 1986

24

MVC

1-6

2-3

2-5 h

3 wk

Klug et al,19 1984

25

11-68

NA

NA

NA

NA

NA

T, 39C-40C; HR, Fentanyl citrate, 140-160 beats/min; pancuronium RR, 40-45 bromide, breaths/min; SBP, lorazepam, 150-160 mm Hg; clonazepam, DBP, 105-115 dantrolene, mm Hg; diaphoresis; bromocriptine, decerebrate acetaminophen, posturing/ methadone, opisthotnous diazepam, propranolol Increased T, HR, RR, Morphine, and BP; dilated dantrolene, pupils; increased bromocriptine extensor posturing; diaphoresis T, 39C-41C, HR, 160 Shunt revision beats/min; RR, 32-36 breaths/min; SBP, 150-158 mm Hg; DBP, 90-100 mm Hg; rigidity; decerebrate posturing; diaphoresis T, 38C-40C; HR, Morphine, 100-150 beats/min; bromocriptine, RR, 60-148 dantrolene breaths/min; SBP, 170-190 mm Hg; DBP, 80-120 mm Hg; extensor/decerebrate posturing; increased ICP; dilated pupils Changes in T, HR, RR, NA BP

Autonomic dysfunction syndrome

Hyperthermic syndrome

Diencephalic seizures

Strich,8 1956

27, 28, 32

TBI

NA

NA

NA

Hyperpnea; extensor posturing; decerebration; salivation; sweating

NA

Decerebrate rigidity and vegetative signs Brainstem attacks

Abbreviations: BP, blood pressure; CHI, closed head injury; CPK, creatine phosphokinase; DBP, diastolic BP; HR, heart rate; ICH, intracranial hemorrhage; ICP, intracranial pressure; MVC, motor vehicle crash; NA, not available; RR, respiratory rate; SBP, systolic BP; T, temperature; TBI, traumatic body injury.

DIFFERENTIAL DIAGNOSIS The following clinical entities have features in common with PAID and may share underlying pathophysiological mechanisms (Table 3). Neuroleptic Malignant Syndrome Neuroleptic malignant syndrome is a severe disturbance of motor tone seen in patients taking dopamine receptor blocking agents, ie, phenothiazines such as thioridazine hydrochloride (Mellaril) and prochlorperazine (Compazine) and butyrophenones such as haloperidol (Haldol). This syndrome consists of fever, muscle rigidity, autonomic instability, alteration of consciousness, and elevation of serum creatine phosphokinase levels. Formerly, neuroleptics such as haloperidol were frequently used to treat agitation in brain-injured patients. The decline in this prac(REPRINTED) ARCH NEUROL / VOL 61, MAR 2004 324

tice has diminished the occurrence of NMS in such patients. Because a considerable number of safer agents are now available, the use of neuroleptics in this setting is generally considered to be contraindicated. Several cases have been reported with withdrawal of dopamine agonists (levodopa/carbidopa22 and amantadine hydrochloride.23 Numerous reports also associate the syndrome with the use of the dopamine receptor antagonist metoclopramide hydrochloride (Reglan),24-27 a drug commonly used to stimulate gastric emptying and reduce aspiration risk in patients with brain injury. Two case reports implicating metoclopramide involved children,28,29 and in 1 case symptoms were likely triggered by metoclopramide but did not reach their full manifestation until after the therapy was discontinued.30 Neuroleptic malignant syndrome apparently results from deficient compensatory mechanisms after blockade of dopaminergic regulation of muscle tone and
WWW.ARCHNEUROL.COM

2004 American Medical Association. All rights reserved. Downloaded From: http://archneur.jamanetwork.com/ on 06/10/2013

Table 2. Drugs Commonly Used for Paroxysmal Autonomic Instability With Dystonia
Drug Bromocriptine mesylate Actions Dopamine D2 agonist T 7h
12

Peak Action 1.6 h

Typical Uses Puerperal lactation suppression, Parkinson disease Hypertension, ADHD

Major Adverse Effects Hyperprolactinemia, mental status changes (eg, confusion, hallucinations), dyskinesia Sedation, hypotension, rebound hypertension with abrupt withdrawal

Typical Dose Range Adults and adolescents, 1.25 mg PO twice daily initially, titrated to 10 to 40 mg/d Children, 5-10 g/kg per day PO given in divided doses; adults, 0.2-1.2 mg/d PO in divided doses Children, 0.5 mg/kg per dose PO given 2 to 4 times daily; adults, 25 mg/d PO given 2-4 times daily up to a maximum of 400 mg Children, 0.05 mg/kg IV or PO, up to 2 mg every 4-8 h; adults, 2-4 mg IV or PO every 4-8 h Children, 0.2-0.5 mg/kg PO every 4-6 h or 0.1-0.2 mg/kg per dose IV; adults, 10-30 mg PO or 2.5-10 mg IV given up to every 4-6 h Children, 0.5-1 mg/kg per day PO given in divided doses; adults, 10-20 mg PO given 2-4 times daily

Clonidine hydrochloride (Catapres)

2-Adrenergic agonist; decreased sympathetic outflow from CNS; decreased BP Dissociates excitation contraction by interfering with Ca++ release from sarcoplasmic reticulum Interacts with GABA receptor site modulating its activity

12-16 h

3-5 h

Dantrolene sodium (Dantrium)

5-9 h

30 min

Muscle relaxation, malignant hyperthermia

Hepatotoxicity, drowsiness, generalized weakness

Lorazepam (Ativan)

12 h

2h

Sedative, anxiolytic anticonvulsant, muscle relaxant Analgesia

Lightheadedness, lassitude, motor incoordinaton, confusion Drowsiness, nausea/vomiting, euphoria, histamine release, hypotension, pruritis, ileus

Morphine sulfate

Opioid -receptor agonist

2h

IV/IM, 30 min

Propranolol hydrochloride (Inderal)

1,2-Adrenergic blockade

3-5 h

90 min

Hypertension, thyrotoxicosis, anxiolytic

Bradycardia, light-headedness, lassitude, weakness, bronchospasm

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; BP, blood pressure; CA++, calcium ion; CNS, central nervous system; GABA, -aminobutyric acid; IM, intramuscular; IV, intravenous; NA, not applicable; PO, by mouth; T , half-life.
12

Table 3. Comparison of Clinical Signs in Conditions That Mimic PAID After Traumatic Brain Injury
Rigidity/ Extensor Posturing + + NA NA NA NA NA NA

Mental Status PAID Malignant hyperthermia Neuroleptic malignant syndrome Increased ICP Central fever Infection/sepsis Nonconvulsive epilepsy Agitation (RLA level IV)* Narcotic withdrawal Autonomic dysreflexia NA NA

Temperature NA NA NA

Heart Rate NA

Breathing Rate NA

Blood Pressure or NA NA NA NA

Pupil Size NA NA NA NA NA

Diaphoresis + NA + NA NA NA + + +

Agitation + NA NA NA NA NA + + NA

CPK ? NA NA NA NA NA NA NA

Myoglobinuria NA + + NA NA NA NA NA NA NA

Abbreviations: CPK, creatine phosphokinase; ICP, intracranial pressure; PAID, paroxysmal autonomic instability with dystonia; RLA, Rancho Los Amigos Scale; downward arrow, decreased; plus sign, increased; plus-minus sign, may or may not be present; upward arrow, increased; question mark, unknown. *Explained in Hagen et al.49

autonomic function. 31 Neuroleptic malignant syndrome occurs in only 1% of individuals taking neuroleptics. The incidence of NMS is likely lower than this with the newer antipsychotic drugs. Cases have been reported in children as young as 1 year after a single accidental dose.32 Symptoms usually occur 3 to 9 days after starting therapy. Extrapyramidal signs may be associated with other NMS clinical features. With early recog(REPRINTED) ARCH NEUROL / VOL 61, MAR 2004 325

nition and appropriate treatment, mortality due to NMS is low. Treatment includes stopping the neuroleptic therapy and providing supportive care. Malignant Hyperthermia Malignant hyperthermia (MH) is a disease of skeletal muscle characterized by hypermetabolism that occurs with
WWW.ARCHNEUROL.COM

2004 American Medical Association. All rights reserved. Downloaded From: http://archneur.jamanetwork.com/ on 06/10/2013

exposure to a triggering agent such as inhalational anesthetic agents or depolarizing muscle relaxant drugs (eg, succinylcholine chloride), usually during induction or sometimes within 2 to 3 hours and rarely more than 24 hours later. After surgery, MH has been reported to occur in the absence of administration of a known triggering agent and may continue for several days.33 Malignant hyperthermia may also follow head injury without any exposure to anesthesia or surgery.34 A 21-year-old man became agitated and diaphoretic 36 hours after head injury. His temperature rose to 42.3C; he was tachycardic, hypotensive, tachypneic, and displayed decerebrate posturing. Rhabdomyolysis and renal and liver failure developed. Results of a muscle biopsy confirmed the diagnosis of MH, including a characteristically abnormal response of muscle to halothane in vitro. Malignant hyperthermia tends to occur most commonly in younger persons; 52% were younger than 15 years in 1 case series.35 Inheritance of MH is primarily autosomal dominant, although it may also be autosomal recessive, polygenic (genes on chromosomes 3, 17, and 19 have been implicated), or sporadic.36-39 Abnormal calcium regulation appears to be the basic underlying defect resulting in tonic muscle contraction with production of excessive heat, resulting in a rise in body temperature to as high as 44C. Skeletal muscle rigidity can be local or diffuse, and is often first observed in the masseter muscles, extremities, and chest. Damaged muscles release large amounts of tissue thromboplastin, leading to coagulopathy, and myoglobin, leading to myoglobinuria and acute tubular necrosis. Apart from discontinuing the triggering agent, if known, the use of dantrolene is the only effective treatment for MH. Dantrolene blocks calcium release from the sarcoplasmic reticulum causing muscle relaxation, and has reduced mortality due to MH dramatically. Diencephalic Seizures The PAID syndrome frequently has been termed and confused with true diencephalic seizures. In 1929, Penfield40 described a 41-year-old women with a tumor of the third ventricle who displayed paroxysmal discharges of the vegetative nervous system that he described as autonomic epilepsy. Subsequent case reports of episodes characterized by irregular respirations, altered heart rate, labile blood pressure, hypothermia, and diaphoresis were associated with neoplasms of the diencephalon,41 agenesis of the corpus callosum,42-44 trapped third ventricle,45 and a suprasellar arachnoid cyst. The key features of hypothermia and profuse sweating generally responded to anticonvulsants, although electroencephalographic studies did not typically show epileptiform discharges. One case of periodic hypothermia, described as diencephalic epilepsy, responded only to total sympathectomy.46 Several cases of what appears to us to be the PAID syndrome have been described in the literature as diencephalic seizures.2,3 Goh et al10 described a 7-year-old child with repeated episodes of sympathetic hyperactivity due to a midbrain glioma as having a variant of diencephalic seizures. They acknowledged in the discussion that the
(REPRINTED) ARCH NEUROL / VOL 61, MAR 2004 326

term seizure is a misnomer, because there has never been a demonstration of an epileptogenic focus during a PAID episode, and most patients with PAID do not benefit from antiepileptic medications. Thus, diencephalic seizures constitute a syndrome distinct from PAID. Autonomic Dysreflexia Autonomic dysreflexia (AD) occurs in individuals with spinal cord injury at the level of T6 through T8 or above. Any noxious stimulus below this level, such as a distended bladder, may initiate reflexive sympathetic activity resulting in life-threatening hypertension uncontrolled by feedback parasympathetic activity.47 Other manifestations of AD include headache, flushing and sweating of the face and upper torso, and apprehension. Removing the inciting stimulus relieves AD. Patients with spinal cord injury may have brain injuries as well, predisposing them to sympathetic dysregulation at the spinal cord and brain levels. Central Fever Fever is common after central nervous system trauma.48 Causes include wound infection, meningitis, blood in the cerebrospinal fluid, drug fever, and pneumonia/ atelectasis. Central fever is a diagnosis of exclusion, attributed to trauma if it affects the base of the brain or the hypothalamus. The fever, often very high and persisting for weeks after injury, is relatively resistant to antipyretic therapy and occurs in the absence of perspiration. Agitation The clinical sign that is probably most often confused with PAID is simple agitation. After emergence from true coma (return of sleep/awake cycles) with returningalbeit sometimes very slowlyarousal and awareness, the patient typically becomes agitated with extensor posturing and thrashing about the bed. The following tabulation shows the levels of cognitive functioning of the Rancho Los Amigos Scale49:
Level I II III IV V VI VII VIII Description No response Generalized response Localized response Confused, agitated Confused, inappropriate Confused, appropriate Automatic, appropriate Purposeful, appropriate

If the patient is at level II, there may be no purposeful movements. The lack of autonomic instability (ie, excessive rise in temperature and blood pressure) distinguishes agitation from PAID. Pain or discomfort from any source (eg, musculoskeletal, visceral, or headache) can produce agitation. When purposeful movements are observed with agitation, such as pulling out tubes or hitting, as seen at Rancho Los Amigos levels III and IV, PAID is clearly not the cause of agitation. Another possible cause of agitation is narcotic withdrawal, as almost all patients with severe brain trauma accompanied by other inWWW.ARCHNEUROL.COM

2004 American Medical Association. All rights reserved. Downloaded From: http://archneur.jamanetwork.com/ on 06/10/2013

juries such as fractures receive narcotics in the intensive care setting, and they are weaned from the drugs as they progress toward rehabilitation. In acute brain injury, the pathophysiology of PAID may be similar in some ways to that of NMS or MH. Drug exposure or withdrawal or even stress may initiate aspects of these conditions, confusing the diagnosis. Any of the single features of PAID, such as hypertension, agitation, or hypertonia, could stimulate the full-blown syndrome. This might explain why a single drug that addresses 1 feature (eg, dantrolene for hypertonia) could interrupt and perhaps abort the process, especially if therapy is initiated early. Four cases of posttraumatic dysautonomia successfully treated with intrathecal baclofen, a muscle relaxant, illustrate this point.11 Most often, more than 1 drug is required for control. It is clear that PAID is not associated with seizure activity and, thus, the term diencephalic or hypothalamic seizure is not appropriate to describe this condition. Unless there are comorbid seizures, antiepileptic drugs for PAID are not a rational choice except for use as mood stabilizers, possibly treating the agitation feature. CRITERIA FOR PAID It seems useful clinically and for future research to establish a single name that encompasses and clearly denotes the main features of the clinical phenomena described in this report. Paroxysmal autonomic instability with dystonia appears to accomplish this. Based on the literature review and our own experience, we propose specific criteria for the PAID syndrome. Within the clinical setting of traumatic brain injury, signs of PAID syndrome include (1) severe brain injury (Rancho Los Amigos level, IV), (2) temperature of at least 38.5C, (3) pulse of at least 130 beats/min, (4) respiratory rate of at least 140 breaths/ min, (5) agitation, (6) diaphoresis, and (7) dystonia (ie, rigidity or decerebrate posturing). The duration is at least 1 cycle per day for at least 3 days. Finally, other conditions must be ruled out. In addition to recognizing consistent features of PAID, it is as important to recognize signs of other diseases or conditions that require prompt attention and a different diagnostic or treatment approach. ASSESSMENT AND TREATMENT Differential diagnosis is challenging, especially in the phase of acute brain injury. Because patients may be heavily sedated for ventilation or pain management, temperature elevation is usually the first concern, prompting body fluid cultures, leukocyte counts, and various imaging studies to rule out sepsis. If these test results are negative, fever may be attributable to noninfectious causes. As sedation and analgesia are withdrawn, more typical cycles of PAID may become evident. Typically, the next sign of concern is elevated blood pressure, leading to the initiation of antihypertensive therapy. Gradually, the cyclical nature of the PAID signs becomes evident with episodes daily or several times daily and with the return of vital signs to normal between episodes. Before accepting PAID as a diagnosis, alternative causes of autonomic dysregulation should be consid(REPRINTED) ARCH NEUROL / VOL 61, MAR 2004 327

ered, especially treatable intracranial abnormalities such as hydrocephalus, increased intracranial pressure, or extraaxial blood or fluid accumulation. Other treatable irritants, such as dehydration, constipation, fracture site pain, or uncomfortable casts must be alleviated. Drugs or anesthetics that might precipitate or exacerbate PAID should be avoided, and caution should be used in the sudden withdrawal of dopamine agonist therapy. As described earlier, a finite number of drugs have been used singly or in combination to alleviate PAID. No clear evidence suggests that one medication regimen is superior to another, and drugs seem to work well for some patients but not others. The goal is to maximize effectiveness while minimizing adverse effects. For example, sedation medications that are administered as needed, like narcotics or benzodiazepines, may quiet an episode but depress arousal and awareness between episodes. Clonidine will reduce blood pressure effectively, but also is sedating. Dantrolene as a muscle relaxant may be preferable to baclofen because it does not sedate; however, its use may be limited by toxic effects to the liver. -Blockers will lessen sympathetic features, but should be used with caution in patients with asthma or diabetes. A logical approach is to choose target signs, consider safety of particular drugs for the individual, and set a time frame for determination of efficacy before a drug is changed or a second drug is added. In our center, we try to devise a regimen that will prevent or ameliorate rather than rely on as-required drugs that may overtreat the condition. Greater awareness of PAID and appropriate early intervention may minimize repetitive and expensive tests (eg, sepsis workups), ease nursing management, avoid pharmacological excess, prevent secondary injury, and allay the anxiety of parents and health care workers observing repeated episodes. Further research is needed to evaluate individual or combination pharmacotherapy for PAID. A clearer definition of this syndrome may facilitate cross-institutional studies. Accepted for publication October 29, 2003. Author contributions: Study concept and design (Drs Blackman and Patrick); acquisition of data (Dr Blackman); analysis and interpretation of data (Drs Blackman, Buck, and Rust); drafting of the manuscript (Drs Blackman and Rust); critical revision of the manuscript for important intellectual content (Drs Blackman, Patrick, Buck, and Rust); administrative, technical, and material support (Drs Blackman, Buck, and Rust); study supervision (Dr Blackman). Corresponding author and reprints: James A. Blackman, MD, MPH, Kluge Childrens Rehabilitation Center, University of Virginia, 2270 Ivy Rd, Charlottesville, VA 22903 (e-mail: jab5u@virginia.edu).
REFERENCES
1. Baguley IJ. Nomenclature of paroxysmal sympathetic storms [letter]. Mayo Clin Proc. 1999;74:105. 2. Bullard DE. Diencephalic seizures: responsiveness to bromocriptine and morphine. Ann Neurol. 1987;21:609-611.

WWW.ARCHNEUROL.COM

2004 American Medical Association. All rights reserved. Downloaded From: http://archneur.jamanetwork.com/ on 06/10/2013

3. Boeve BF, Wijdicks EFM, Benarroch EE, Schmidt KD. Paroxysmal sympathetic storms (diencephalic seizures) after severe head injury. Mayo Clin Proc. 1998; 73:148-152. 4. Nosuka S. Hypertension induced by extensive medial anteromedian hypothalamic destruction in the rat. Jpn Circ J. 1966;30:509-523. 5. Reis DJ, Gauthier P, Nathan MA. Hypertension, adrenal catecholamine release, pulmonary edema, and behavioral excitement elicited from the anterior hypothalamus in rat. In: Usdin E, Kvetnansky R, Kopin I, eds. Catecholamines and Stress. Elmsford, NY: Pergamon Press Inc; 1976:195-206. 6. Kupferman I. Hypothalamus and limbic system, II: motivation. In: Kandel ER, Schwartz JH, eds. Principles of Neuroscience. New York, NY: Elsevier Science Publishers; 1985:626-635. 7. Guyton AC, Hall JE. Textbook of Medical Physiology. Philadelphia, Pa: WB Saunders Co; 2000:622. 8. Strich SJ. Diffuse degeneration of the cerebral white matter in severe dementia. J Neurol Neurosurg Psychiatry. 1956;19:163-185. 9. Do D, Sheen VL, Bromfield E. Treatment of paroxysmal sympathetic storm with labetalol. J Neurol Neurosurg Psychiatry. 2000;69:832-833. 10. Goh KYC, Conway EJ, DaRosso RC, Muszynski CA, Epstein FJ. Sympathetic storms in a child with midbrain glioma: a variant of diencephalic seizures. Pediatr Neurol. 1999;21:742-744. 11. Cuny E, Richer E, Castel JP. Dysautonomia syndrome in the acute recovery phase after traumatic brain injury: relief with intrathecal baclofen therapy. Brain Inj. 2001;15:917-925. 12. Thorley RR, Wertsh JJ, Klingbeil GE. Acute hypothalamic instability in traumatic brain injury: a case report. Arch Phys Med Rehabil. 2001;82:246-249. 13. Scott JS, Ockey RR, Holmes GE, Varhese G. Autonomic dysfunction associated with locked-in syndrome in a child. Am J Phys Med Rehabil. 1997;76:200-203. 14. Sneed RC. Hyperpyrexia associated with sustained muscle contractions: an alternative diagnosis to central fever. Arch Phys Med Rehabil. 1995;76:101-103. 15. Meythaler JM, Stinson AM III. Fever of central origin in traumatic brain injury controlled with propranolol. Arch Phys Med Rehabil. 1994;75:816-818. 16. Pranzatelli MR, Paviakis SG, Gould RJ, De Vivo DC. Hypothalamic-midbrain dysregulation syndrome: hypertension, hyperthermia, hyperventilation, and decerebration. J Child Neurol. 1991;6:115-122. 17. Rossitch E Jr, Bullard DE. The autonomic dysfunction syndrome: aetiology and treatment. Br J Neurosurg. 1988;2:471-478. 18. Talman WT, Florek G, Bullard DE. A hyperthermic syndrome in two subjects with acute hydrocephalus. Arch Neurol. 1988;45:1037-1040. 19. Klug N, Hoffman O, Zierski J, Buss K, Laun A, Agnoli AL. Decerebrate rigidity and vegetative signs in the acute midbrain syndrome with special regard to motor activity and intracranial pressure. Acta Neurochir (Wein). 1984;72:219-233. 20. Siren A-L, Feuerstein G. The opioid system in circulatory control. News Physiol Sci. 1992;7:26-30. 21. Holaday JW. Cardiovascular effects of endogenous opiate systems. Annu Rev Pharmacol Toxicol. 1983;23:541-594. 22. Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. JAMA. 1985;254:2792-2795. 23. Toru M, Matsuda O, Makiguchi K, Sugano K. Neuroleptic malignant syndrome like state following a withdrawal of antiparkinsonian drugs. J Nerv Ment Dis. 1981; 169:324-327. 24. Donnet A, Harle JR, Dumont JC, Alif CA. Neuroleptic malignant syndrome induced by metoclopramide. Biomed Pharmacother. 1991;45:461-462. 25. Bakri YN, Khan R, Subhi J, Kawi Z. Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy. Gynecol Oncol. 1992;44:189-190.

26. Patterson JF. Neuroleptic malignant syndrome associated with metoclopramide. South Med J. 1988;81:674-675. 27. Friedman LS, Weinrauch LA, DElia JA. Metoclopramide-induced neuroleptic malignant syndrome. Arch Intern Med. 1987;147:1495-1497. 28. Shaw A, Matthews EE. Postoperative neuroleptic malignant syndrome. Anaesthesia. 1995;50:246-247. 29. Brower RD, Dreyer CF, Kent TA. Neuroleptic malignant syndrome in a child treated with metoclopramide for chemotherapy-related nausea. J Child Neurol. 1989;4: 230-232. 30. Le Couteur DG, Kay T. Delayed neuroleptic malignant syndrome following cessation of prolonged therapy with metoclopramide [letter]. Aust N Z J Med. 1995; 25:261. 31. Pearlman CA. Neuroleptic malignant syndrome: a review of the literature. J Clin Psychopharmacol. 1986;6:257-273. 32. Klein SK, Levinsohn MW, Blumer JL. Accidental chlorpromazine ingestion as a cause of neuroleptic malignant syndrome in children. J Pediatr. 1985;107:970973. 33. Pollock N, Hodges M, Sendall J. Prolonged malignant hyperthermia in the absence of triggering agents. Anaesth Intensive Care. 1992;20:520-523. 34. Feuerman T, Gade GF, Reynolds R. Stress-induced malignant hyperthermia in a head-injured patient: case report. J Neurosurg. 1988;68:297-299. 35. Strazis KP, Fox AW. Malignant hyperthermia: a review of published cases. Anesth Analg. 1993;77:297-304. 36. Britt BA, Kalow W. Malignant hyperthermia: a statistical review. Can Anaesth Soc J. 1970;17:293-315. 37. Kalow W, Britt BA, Terreau ME, Haist C. Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet. 1970;2:895-898. 38. Isaacs H, Barlow MB. The genetic background to malignant hyperpyrexia revealed by serum creatine phosphokinase estimations in asymptomatic relatives. Br J Anaesth. 1970;42:1077-1084. 39. McPherson E, Taylor CA Jr. The genetics of malignant hyperthermia: evidence for heterogeneity. Am J Med Genet. 1982;11:273-285. 40. Penfield W. Diencephalic autonomic epilepsy. Arch Neurol Psychiatry. 1929;22: 358-374. 41. Solomon GE. Diencephalic autonomic epilepsy caused by a neoplasm. J Pediatr. 1973;83:277-280. 42. Shapiro WR, Williams GH, Plum F. Spontaneous recurrent hypothermia accompanying agenesis of the corpus callosum. Brain. 1969;92:423-436. 43. Carr-Locke D, Millac P. Diencephalic epilepsy in a patient with agenesis of the corpus callosum confirmed by computerized axial tomography. J Neurol Neurosurg Psychiatry. 1977;40:808-814. 44. LeWitt PA, Newman RP, Greenberg HS, Rocher LL, Calne DB, Ehrenkranz JR. Episodic hyperhidrosis, hypothermia, and agenesis of corpus callosum. Neurology. 1983;33:1122-1129. 45. Darnell RB, Arbit E. Reversible diencephalic dysfunction: episodic hyperhidrosis due to a trapped third ventricle. Neurology. 1993;43(3, pt 1):579-582. 46. Fox RH, Wilkins DC, Bell JA, et al. Spontaneous periodic hypothermia: diencephalic epilepsy. BMJ. 1973;2:693-695. 47. Lee BY, Karmaker MG, Herz BL, Sturgill RA. Autonomic dysreflexia revisited. J Spinal Cord Med. 1995;18:75-87. 48. Cunha BA, Tu RP. Fever in the neurosurgical patient. Heart Lung. 1988;17(6, pt 1):608-611. 49. Hagen C, Malkmus D, Durham P. Levels of Cognitive Functioning. Downey, Calif: Rancho Los Amigos Hospital; 1979.

(REPRINTED) ARCH NEUROL / VOL 61, MAR 2004 328

WWW.ARCHNEUROL.COM

2004 American Medical Association. All rights reserved. Downloaded From: http://archneur.jamanetwork.com/ on 06/10/2013